$LRMR

Larimar Therapeutics (LRMR) shares rose 3% after hours as director Thomas E. Hamilton bought 50,000 shares for $166,890. Hamilton now owns 714,798 shares directly and 159,433 indirectly. The company is developing nomlabofusp for Friedreich’s ataxia and recently submitted a BLA module to the FDA. H.C. Wainwright initiated coverage with a 'Buy' rating and $10 target, forecasting potential approval and significant sales.

Larimar Therapeutics, Inc. (LRMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update • Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinica

Larimar Therapeutics (NASDAQ:LRMR) filed the first module of its Biologics License Application with the U.S. FDA for Nomlabofusp therapy on an accelerated basis, with additional modules planned in the second half of 2026. The company cited positive open-label study results in adult Friedreich’s ataxia patients and said FDA confirmed existing data supports the submission using skin frataxin as a surrogate endpoint. Baird cut its price target to $5 from $7 while keeping an Outperform rating.

Larimar Therapeutics Inc (NASDAQ:LRMR) shares rose 15.5% after director Thomas Edward Hamilton bought 50,000 shares, according to an SEC Form 4. The weighted average price was $3.3378, with trades between $3.33 and $3.35. Hamilton now owns 714,798 shares directly, plus 159,433 indirectly via Post Edison, LLC.

Hamilton Thomas Edward purchased 50,000 shares of Larimar Therapeutics, Inc. (LRMR) at $3.34 ($0.17M total) on 2026-07-06.

A roundup of analysts’ June 30 price-target changes across many stocks. Examples: Wells Fargo raised AAL to $17 from $12; Leerink raised ABVX to $148 from $140; JPMorgan cut ACI to $20 from $22; Jefferies cut ALB to $211 from $244; Goldman cut APA to $32 from $34; KeyCorp raised ATI to $211 from $175.

Larimar Therapeutics said it will host an investor webcast on Monday, June 29, 2026 at 7:45 a.m. ET to update on its Nomlabofusp program for Friedreich’s ataxia. The company plans to discuss a regulatory update and data from an ongoing Phase 2 long-term open-label study. Larimar also outlined use of its intracellular delivery platform for other rare diseases.

Analysts issued multiple rating and price-target changes across Wall Street. JPMorgan upgraded Openlane to overweight and raised its Dec 2026 PT to $38; UBS upgraded Ecolab to buy with a $325 PT; Barclays upgraded SanDisk to overweight. Micron’s PT was raised to $1,175 by Barclays. JPMorgan upgraded FedEx to overweight ahead of late-June earnings.

Larimar Therapeutics director Joseph Truitt was granted 55,150 stock options with an exercise price of $3.33 per share, expiring on May 19, 2036. These options vest on the earlier of May 19, 2027, or the date of the next annual meeting, contingent on his continued service on the Board of Directors. Following this grant, Truitt directly holds 55,150 stock options.

Larimar Therapeutics director Frank E. Thomas was granted 55,150 stock options as equity compensation, with an exercise price of $3.33 per share. These options vest on the earlier of May 19, 2027, or the date of the next annual stockholder meeting, contingent on his continued service on the board. This transaction is considered a routine, service-based incentive rather than an open-market trade.